Tesamorelin

Tesamorelin (Egrifta) is a potent synthetic analogue of Growth Hormone Releasing Hormone (GHRH), FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy. It is widely used off-label for general visceral fat reduction and anti-aging. Tesamorelin stimulates the pituitary to release growth hormone in a pulsatile manner, which then triggers IGF-1 production. It is unique among GHRH peptides for its specific efficacy in targeting visceral adipose tissue (VAT) and improving metabolic markers like triglycerides. It has a relatively short half-life and is typically dosed daily.

Administer 1–2 mg subcutaneously once daily, typically in the morning or before bed. The clinical dose for visceral fat reduction is 2 mg daily. It is best taken on an empty stomach to maximize GH release. Cycles are often 3–6 months to see significant visceral fat reduction. Reconstitute carefully as it can be fragile.